Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance

Inclusion Criteria

• •1. Males and females aged 18-75 years.
• •2. Recipients of first or secondary cadaveric, living unrelated or living related kidney transplant.
• •3. Recipients who are at least 4 weeks post renal transplantation.
• •4. Patients currently receiving MMF (all dosages are allowed), cyclosporine microemulsion, its generic equivalent, cyclosporine USP (modified) or tacrolimus with or without corticosteroids as part of their immunosuppressive regimen for at least 2 weeks.
• •5. Patients with mild and/or moderate GI complaints (e.g. upper abdominal pain, dyspepsia, anorexia, nausea, vomiting) with or without diarrhea.